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(standing in light for a period of 24 h) can probably 
reveal this metabolic disorder.
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Sir,
A 64-year-old woman was hospitalized for evaluation of a 
25-year history of low back pain and discomfort in the knees. 
Physical examination revealed bluish-black pigmentations 
of the ear cartilage and antihelix, and dark pigmentation 
of the sclera on both eyes in the interpalpebral fissures 
[Figure 1]. Blue-black discoloration was visible on lateral 
aspect of the fingers and nailbeds [Figure 2]. Inflammatory 
markers, calcium, phosphorus, rheumatoid factor, and 
HLA-B27 were normal. On x-rays, sacroiliac joints were 
found to be normal, but the lumbar spine showed loss 
of lordosis, osteophytes, and wafer-like calcification of 
intervertebral discs [Figure 3]. The urine turned black 
on exposure to air or Benedict’s reagent. Measurement 
of urinary organic acid levels showed a large quantity of 
homogentisic acid, which is consistent with ochronosis. 
The patient was treated symptomatically with analgesics 
and was given vitamin C and nitisinone. One year after the 
treatment, the patient only complained of mild back pain. 
Alkaptonuria is an autosomal recessive disorder of 
metabolism caused by the deficiency of homogentisic 
acid oxidase (HGA) and resulting in accumulation of 
homogentisic acid in collagenous structures. The incidence 
of alkaptonuria was estimated at 1:250,000-1:1,000,000 live 
births.[1] Alkaptonuria has three major features:
a Homogentisic aciduria;
b. Ochronosis; and
c. Arthritis, usually in the fourth decade of life.
The least expensive screening test to perform is the urine 
oxidation test, i.e., having it standing in light for a period 
of 24 h when suspicion has risen.[2] No effective therapy is 
available for ochronosis. Dietary restriction of tyrosine and 
phenylalanine will reduce the excretion of HGA, although 
the clinical effect is limited.[3] Pharmacologic treatment of 
alkaptonuria with oral administration of nitisinone has been 
proposed. Nitisinone inhibits 4-hydroxyphenylpyruvate 
dioxygenase, the enzyme that produces HGA.[4] High dose 
of vitamin C decreases urinary benzoquinone acetic acid, a 
derivative of HGA, but it has no effect on HGA excretion. 
It has been hypothesized that high dose of ascorbic acid 
may prevent the deposition of ochronotic pigment, 
although it does not alter the basic metabolic defect.[5]
Based on the findings of this clinical study, it is highly 
recommended that in the patients presented with 
spondylosis, associated with bluish-black pigmentation 
of connective tissue, performing urine oxidation test 
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Figure 1: Dark pigmentation of the sclera on eye in the interpalpebral fissures
Figure 2: Blue-black discoloration was visible on lateral aspect of the 
fingers and nailbeds
Figure 3: Lumbar x-ray showed osteophytes and wafer-like calcification 
of intervertebral discs
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